deferoxamine has been researched along with Dementia in 17 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Dementia: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ultrafiltration experiments, using Amicon membranes with molecular weight exclusions of 1,000, 10,000 and 30,000 daltons, have revealed that Desferal, both in vitro and in vivo, markedly increases aluminum ultrafilterability in plasma from patients with dialysis dementia." | 7.67 | Aluminum-binding protein in dialysis dementia. II. Characterization in plasma by ultrafiltration. ( Agness, C; Gonick, HC; Khalil-Manesh, F, 1989) |
| "Five patients with chronic renal failure, complicated by bone aluminum toxicity, were treated with deferoxamine (DFO)." | 5.27 | Precipitation of dialysis dementia by deferoxamine treatment of aluminum-related bone disease. ( Boykin, JL; Sherrard, DJ; Walker, JV, 1988) |
| "Ultrafiltration experiments, using Amicon membranes with molecular weight exclusions of 1,000, 10,000 and 30,000 daltons, have revealed that Desferal, both in vitro and in vivo, markedly increases aluminum ultrafilterability in plasma from patients with dialysis dementia." | 3.67 | Aluminum-binding protein in dialysis dementia. II. Characterization in plasma by ultrafiltration. ( Agness, C; Gonick, HC; Khalil-Manesh, F, 1989) |
| "We describe a patient undergoing chronic hemodialysis who developed a neurologic syndrome consisting of seizures, progressive myoclonus, and mild dementia and who responded to chelation therapy with deferoxamine mesylate." | 3.67 | Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity. ( Corwin, HL; Mayor, GH; Sprague, SM; Tanner, CM; Wilson, RS, 1986) |
| " Twenty-four patients, 15 with dialysis osteomalacia and nine with clinically apparent secondary hyperparathyroidism, had serum aluminum levels measured before and after a standard infusion of a chelating agent, deferoxamine (DFO)." | 3.67 | Do serum aluminum levels reflect underlying skeletal aluminum accumulation and bone histology before or after chelation by deferoxamine? ( Brown, P; Cordy, PE; Hodsman, AB; Hood, SA, 1985) |
| "Five patients with dialysis encephalopathy were transferred to deionized water; all died after a variable period, 4 of progressive dementia." | 1.27 | The effect of low aluminum water and desferrioxamine on the outcome of dialysis encephalopathy. ( Bell, P; Meyers, AM; Milne, FJ; Sharf, B, 1983) |
| "Five patients with chronic renal failure, complicated by bone aluminum toxicity, were treated with deferoxamine (DFO)." | 1.27 | Precipitation of dialysis dementia by deferoxamine treatment of aluminum-related bone disease. ( Boykin, JL; Sherrard, DJ; Walker, JV, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (58.82) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 1 (5.88) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Mielke, N | 1 |
| Johnson, S | 1 |
| Bahl, A | 1 |
| Fadladdin, YAJ | 1 |
| Xue, M | 1 |
| Zhang, X | 1 |
| Chen, J | 1 |
| Liu, F | 1 |
| Xu, J | 1 |
| Xie, J | 1 |
| Yang, Y | 1 |
| Yu, W | 1 |
| Qiu, H | 1 |
| Xue, J | 1 |
| Jiang, J | 1 |
| Liu, Y | 2 |
| Shallom, SJ | 1 |
| Zelazny, AM | 1 |
| Giri, AR | 1 |
| Kaur, N | 1 |
| Yarrarapu, SNS | 1 |
| Rottman Pietrzak, KA | 1 |
| Santos, C | 1 |
| Lowman, PE | 1 |
| Niaz, S | 1 |
| Franco, PM | 1 |
| Sanghavi, DK | 1 |
| Zhu, D | 1 |
| Liang, R | 1 |
| Li, Z | 2 |
| Cheng, L | 1 |
| Ren, J | 1 |
| Guo, Y | 1 |
| Wang, M | 1 |
| Chai, H | 1 |
| Niu, Q | 1 |
| Yang, S | 1 |
| Bai, J | 1 |
| Yu, H | 1 |
| Zhang, H | 1 |
| Qin, X | 1 |
| Sahrakorpi, N | 1 |
| Engberg, E | 1 |
| Stach-Lempinen, B | 1 |
| Tammelin, TH | 1 |
| Kulmala, J | 1 |
| Roine, RP | 1 |
| Koivusalo, SB | 1 |
| Cheng, W | 1 |
| Pang, H | 1 |
| Campen, MJ | 1 |
| Zhang, J | 2 |
| Li, Y | 1 |
| Gao, J | 1 |
| Ren, D | 1 |
| Ji, X | 1 |
| Rothman, N | 1 |
| Lan, Q | 1 |
| Zheng, Y | 1 |
| Leng, S | 1 |
| Hu, Z | 1 |
| Tang, J | 1 |
| Dong, Q | 1 |
| Song, N | 1 |
| Qin, N | 1 |
| Chen, C | 1 |
| Sun, X | 1 |
| Easton, J | 1 |
| Mulder, H | 1 |
| Plyler, E | 1 |
| Neale, G | 1 |
| Walker, E | 1 |
| Li, Q | 1 |
| Ma, X | 1 |
| Chen, X | 1 |
| Huang, IC | 1 |
| Yasui, Y | 1 |
| Ness, KK | 1 |
| Hudson, MM | 1 |
| Robison, LL | 1 |
| Wang, Z | 1 |
| Subota, A | 1 |
| Spotswood, N | 1 |
| Roach, M | 1 |
| Goodarzi, Z | 1 |
| Holroyd-Leduc, J | 1 |
| Park, EA | 1 |
| Graves, SA | 1 |
| Menda, Y | 1 |
| Tseng, YJ | 1 |
| Chen, CH | 1 |
| Chen, WK | 1 |
| Dong-Zong, H | 1 |
| Kinugasa, E | 1 |
| Yamamoto, M | 1 |
| Fukui, T | 1 |
| Kashiwagi, T | 1 |
| Kurihara, S | 1 |
| Shore, D | 1 |
| Wyatt, RJ | 1 |
| Hood, SA | 2 |
| Clark, WF | 1 |
| Hodsman, AB | 2 |
| Bolton, CF | 1 |
| Cordy, PE | 2 |
| Anderson, C | 1 |
| Leung, F | 1 |
| Milne, FJ | 1 |
| Sharf, B | 1 |
| Bell, P | 1 |
| Meyers, AM | 1 |
| Cutler, P | 1 |
| Ogura, Y | 1 |
| Yokoyama, K | 1 |
| Ohara, M | 1 |
| Verbeelen, D | 1 |
| Khalil-Manesh, F | 1 |
| Agness, C | 1 |
| Gonick, HC | 1 |
| McLachlan, DR | 1 |
| Kruck, TP | 1 |
| VanBerkum, MF | 1 |
| Sherrard, DJ | 1 |
| Walker, JV | 1 |
| Boykin, JL | 1 |
| Sprague, SM | 1 |
| Corwin, HL | 1 |
| Wilson, RS | 1 |
| Mayor, GH | 1 |
| Tanner, CM | 1 |
| Swartz, RD | 1 |
| Weiland, P | 1 |
| Köhler, M | 1 |
| Glatzel, E | 1 |
| Brown, P | 1 |
6 reviews available for deferoxamine and Dementia
| Article | Year |
|---|---|
Topics: Adult; Aging; Aluminum; Alzheimer Disease; Animals; Anti-Bacterial Agents; Artemisia annua; Body Mas | 2022 |
[Dialysis encephalopathy].
Topics: Aluminum; Deferoxamine; Dementia; Diagnosis, Differential; Dialysis; Dialysis Solutions; Drug Contam | 2004 |
[Aluminum and iron deposition in dialysis patients].
Topics: Aluminum; Aluminum Hydroxide; Anemia; Bone Diseases, Metabolic; Contraindications; Deferoxamine; Dem | 2004 |
Aluminum and Alzheimer's disease.
Topics: Aluminum; Alzheimer Disease; Animals; Brain Chemistry; Cell Nucleus; Cooking and Eating Utensils; De | 1983 |
Aluminum and neurodegenerative disease: therapeutic implications.
Topics: Aluminum; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Brain; Calcium; Deferoxamine; D | 1985 |
Deferoxamine and aluminum removal.
Topics: Aluminum; Bone and Bones; Chelating Agents; Deferoxamine; Dementia; Humans; Iron; Osteomalacia; Peri | 1985 |
11 other studies available for deferoxamine and Dementia
| Article | Year |
|---|---|
Hand warmer related corrosive injury.
Topics: Accidents, Home; Aged, 80 and over; Aluminum Silicates; Burns, Chemical; Charcoal; Deferoxamine; Dem | 2011 |
Successful treatment of dialysis osteomalacia and dementia, using desferrioxamine infusions and oral 1-alpha hydroxycholecalciferol.
Topics: Aluminum; Biopsy; Bone and Bones; Deferoxamine; Dementia; Female; Glomerulonephritis; Hemodialysis, | 1984 |
The effect of low aluminum water and desferrioxamine on the outcome of dialysis encephalopathy.
Topics: Adult; Aged; Aluminum; Bone Diseases; Brain Diseases; Deferoxamine; Dementia; Electroencephalography | 1983 |
Iron overload and psychiatric illness.
Topics: Adult; Aged; Anxiety Disorders; Carrier Proteins; Deferoxamine; Dementia; Depressive Disorder; Diagn | 1994 |
[Dialysis encephalopathy].
Topics: Anticonvulsants; Apraxias; Deferoxamine; Dementia; Electroencephalography; Humans; Kidney Failure, C | 1992 |
Aluminum toxicity.
Topics: Aluminum; Anemia; Animals; Deferoxamine; Dementia; Disease Models, Animal; Humans; Kidney Failure, C | 1991 |
Aluminum-binding protein in dialysis dementia. II. Characterization in plasma by ultrafiltration.
Topics: Aluminum; Carrier Proteins; Deferoxamine; Dementia; Humans; Molecular Weight; Renal Dialysis; Ultraf | 1989 |
Precipitation of dialysis dementia by deferoxamine treatment of aluminum-related bone disease.
Topics: Adult; Aluminum; Bone Diseases; Deferoxamine; Dementia; Female; Humans; Kidney Failure, Chronic; Mal | 1988 |
Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity.
Topics: Aluminum; Deferoxamine; Dementia; Female; Humans; Kidney Failure, Chronic; Middle Aged; Myoclonus; R | 1986 |
[Successful treatment of progressive dialysis encephalopathy. Case report].
Topics: Aluminum; Deferoxamine; Dementia; Electroencephalography; Evoked Potentials; Female; Humans; Kidney | 1985 |
Do serum aluminum levels reflect underlying skeletal aluminum accumulation and bone histology before or after chelation by deferoxamine?
Topics: Adult; Aluminum; Biopsy; Bone and Bones; Deferoxamine; Dementia; Humans; Hyperparathyroidism, Second | 1985 |